NanoViricides (NNVC) Competitors $1.32 -0.04 (-2.57%) As of 02:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NNVC vs. ORMP, MGX, CNTX, SLGL, IPA, IMUX, ANEB, HOWL, ADAG, and PLRXShould you be buying NanoViricides stock or one of its competitors? The main competitors of NanoViricides include Oramed Pharmaceuticals (ORMP), Metagenomi (MGX), Context Therapeutics (CNTX), Sol-Gel Technologies (SLGL), ImmunoPrecise Antibodies (IPA), Immunic (IMUX), Anebulo Pharmaceuticals (ANEB), Werewolf Therapeutics (HOWL), Adagene (ADAG), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry. NanoViricides vs. Its Competitors Oramed Pharmaceuticals Metagenomi Context Therapeutics Sol-Gel Technologies ImmunoPrecise Antibodies Immunic Anebulo Pharmaceuticals Werewolf Therapeutics Adagene Pliant Therapeutics NanoViricides (NYSE:NNVC) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk. Do insiders & institutionals hold more shares of NNVC or ORMP? 10.3% of NanoViricides shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 4.6% of NanoViricides shares are held by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend NNVC or ORMP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oramed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has stronger earnings and valuation, NNVC or ORMP? NanoViricides has higher earnings, but lower revenue than Oramed Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanoViricidesN/AN/A-$8.29M-$0.64-2.07Oramed Pharmaceuticals$1.34M72.82-$19.06M-$0.35-6.80 Which has more volatility and risk, NNVC or ORMP? NanoViricides has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Is NNVC or ORMP more profitable? Oramed Pharmaceuticals' return on equity of -19.37% beat NanoViricides' return on equity.Company Net Margins Return on Equity Return on Assets NanoViricidesN/A -87.90% -78.69% Oramed Pharmaceuticals N/A -19.37%-18.28% Does the media prefer NNVC or ORMP? In the previous week, Oramed Pharmaceuticals had 3 more articles in the media than NanoViricides. MarketBeat recorded 3 mentions for Oramed Pharmaceuticals and 0 mentions for NanoViricides. Oramed Pharmaceuticals' average media sentiment score of 0.62 beat NanoViricides' score of 0.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment NanoViricides Neutral Oramed Pharmaceuticals Positive SummaryOramed Pharmaceuticals beats NanoViricides on 10 of the 12 factors compared between the two stocks. Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NNVC vs. The Competition Export to ExcelMetricNanoViricidesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$23.11M$1.01B$6.06B$21.92BDividend YieldN/A4.84%5.73%3.67%P/E Ratio-1.841.3085.4529.93Price / SalesN/A30.04593.9092.75Price / CashN/A17.6425.7717.79Price / Book2.017.6412.694.70Net Income-$8.29M-$7.59M$3.32B$1.01B7 Day Performance-6.36%9.87%0.54%0.22%1 Month Performance-8.62%21.70%9.47%1.61%1 Year Performance-7.34%-11.12%79.06%14.51% NanoViricides Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NNVCNanoViricides0.093 of 5 stars$1.33-2.6%N/A-8.7%$23.11MN/A-1.8420ORMPOramed Pharmaceuticals1.0221 of 5 stars$2.45+0.4%N/A+1.3%$100.05M$1.34M-7.0010MGXMetagenomi3.2548 of 5 stars$2.69+1.5%$10.00+271.7%+45.4%$99.46M$52.29M-1.14236Gap UpCNTXContext Therapeutics3.2042 of 5 stars$1.21+10.0%$5.20+329.8%-28.1%$98.68MN/A-3.367High Trading VolumeSLGLSol-Gel Technologies0.6172 of 5 stars$42.90+23.3%N/A+487.5%$96.95M$23.93M-34.8850Gap DownHigh Trading VolumeIPAImmunoPrecise Antibodies1.037 of 5 stars$2.10+8.5%$4.00+90.9%+256.3%$96.68M$17.59M-3.0880Gap UpIMUXImmunic2.2088 of 5 stars$0.94-3.9%$9.50+910.6%-36.1%$96.51MN/A-1.0070ANEBAnebulo Pharmaceuticals2.7956 of 5 stars$2.33+0.9%$5.50+136.1%+23.4%$94.91MN/A-8.964HOWLWerewolf Therapeutics3.4619 of 5 stars$2.03-1.0%$8.00+294.1%-18.5%$93.74M$1.88M-1.2440Gap UpADAGAdagene2.4953 of 5 stars$1.99+0.5%$7.00+251.8%-9.9%$93.32M$100K0.00260PLRXPliant Therapeutics4.0644 of 5 stars$1.49-2.0%$8.19+449.5%-89.1%$93.31M$1.58M-0.4490 Related Companies and Tools Related Companies Oramed Pharmaceuticals Alternatives Metagenomi Alternatives Context Therapeutics Alternatives Sol-Gel Technologies Alternatives ImmunoPrecise Antibodies Alternatives Immunic Alternatives Anebulo Pharmaceuticals Alternatives Werewolf Therapeutics Alternatives Adagene Alternatives Pliant Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NNVC) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
